NPRC/Institute
Meissa Vaccines Inc; Bill & Melinda Gates Foundation; BIOQUAL Inc; Butler University; Vanderbilt University School of Medicine; University of Texas Medical Branch
Summary of Study
A live, attenuated, recombinant human respiratory virus that expresses a chimeric SARS-CoV-2 spike protected against challenge and induced immunoglobulin and neutralizing antibodies.
Year Published
2022
References
PMID: 35906244 / doi: 10.1038/s41541-022-00509-6
Contact Info
Mariana F. Tioni: mariana.tioni@meissavaccines.com
Keywords
SARS-CoV-2, attenuated recombinant vaccine, immune response, primates
Coronavirus Investigated*
NHP Species
date entered
Study Type